First PREMIER Bank’s SAB Biotherapeutics SABS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $74K | Hold |
18,986
| – | – | 0.01% | 219 |
|
|
2026
Q1 | $73K | Hold |
18,986
| – | – | 0.02% | 210 |
|
|
2025
Q4 | $71K | Hold |
18,986
| – | – | 0.02% | 208 |
|
|
2025
Q3 | $38K | Hold |
18,986
| – | – | 0.01% | 248 |
|
|
2025
Q2 | $33K | Hold |
18,986
| – | – | 0.01% | 249 |
|
|
2025
Q1 | $26K | Hold |
18,986
| – | – | 0.01% | 260 |
|
|
2024
Q4 | $72K | Sell |
18,986
-400
| -2% | -$1.31K | 0.02% | 208 |
|
|
2024
Q3 | $52K | Hold |
19,386
| – | – | 0.01% | 231 |
|
|
2024
Q2 | $60K | Buy |
+19,386
| New | +$71.1K | 0.02% | 201 |
|
|
2024
Q1 | – | Sell |
-80,754
| Closed | -$555K | – | 509 |
|
|
2023
Q4 | $555K | Hold |
80,754
| – | – | 0.16% | 101 |
|
|
2023
Q3 | $509K | Hold |
80,754
| – | – | 0.16% | 100 |
|
|
2023
Q2 | $670K | Hold |
80,754
| – | – | 0.19% | 90 |
|
|
2023
Q1 | $355K | Hold |
80,754
| – | – | 0.1% | 116 |
|
|
2022
Q4 | $476K | Hold |
80,754
| – | – | 0.14% | 95 |
|
|
2022
Q3 | $566K | Buy |
80,754
+15,510
| +24% | +$154K | 0.18% | 90 |
|
|
2022
Q2 | $946K | Buy |
+65,244
| New | +$1.37M | 0.28% | 76 |
|
|
2022
Q1 | – | Sell |
-83,256
| Closed | -$6.5M | – | 383 |
|
|
2021
Q4 | $6.5M | Buy |
+83,256
| New | +$7.81M | 1.68% | 16 |
|
Other funds holding SABS
First PREMIER Bank's SABS Position: Q2 2026 in Review
First PREMIER Bank held its SAB Biotherapeutics (SABS) position steady in Q2 2026 at 18,986 shares worth $74K. The position accounts for 0.01% of the portfolio, ranked #219.
First PREMIER Bank first reported a position in SABS in Q4 2021 and has held it in 17 quarters since. The position peaked at $6.5M in Q4 2021. 3 funds tracked by Wall St. Rank hold SABS as of Q2 2026.
- First PREMIER Bank held 18,986 shares of SAB Biotherapeutics worth $74K as of Q2 2026.
- First PREMIER Bank left its SAB Biotherapeutics share count unchanged in Q2 2026.
- SAB Biotherapeutics made up 0.01% of First PREMIER Bank's portfolio in Q2 2026, its #219 holding.
- First PREMIER Bank first reported a position in SAB Biotherapeutics in Q4 2021 and has held it in 17 quarters since.
- First PREMIER Bank's SAB Biotherapeutics position peaked at $6.5M in Q4 2021.
- 3 funds tracked by Wall St. Rank held SAB Biotherapeutics as of Q2 2026.
Based on First PREMIER Bank's 13F filing for Q2 2026, filed 15 Jul 2026.